Programme at the Glance

Programme at the Glance –
Thursday 14 October 2021

08.45
09.45

Belgian Society for Thrombosis and Haemostasis

Chair: Jan Emmerechts and Phu Quoc Lee
BSTH.1.1 – 08.45 – 08.50 Introduction by the President of the BSTH
BSTH.1.2 – 08.50 – 09.15 Thrombotic antiphospholipid syndrome – Katrien Devreese, Ghent
BSTH.1.3 – 09.15 – 09.45 Inherited antithrombin deficiency revisited: novel insights in laboratory diagnosis and clinical presentation – Christelle Orlando, Brussel

09.45
10.15

Coffee Break and Poster Viewing

10.15
11.00

Belgian Society for Thrombosis and Haemostasis

Chairs: Simon Demeyer and Thomas Vanassche
BSTH.2.1 – 10.15 – 10.40 Importance of the novo lipogenesis in platelet production and function – Sandrine Horman, Louvain-la-Neuve
BSTH.2.1 – 10.40 – 11.00 Ticagrelor: a potent antiplatelet drug with unprecedented anti-staphylococcal activity – Cécile Oury , Luik

11.00
11.15

Short Break

11.15
12.00

Belgian Society for Thrombosis and Haemostasis

Chairs: Kristin Jochmans and Philip Maes
BSTH.3.1 – 11.15 – 11.30 Presentation by the winner of the Clinical/Laboratory prize – First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination, Severine De Bruijn, Antwerp
BSTH.3.2 – 11.30 – 11.45 Presentation by the winner of the Basic science prize – Neutrophils promote the progression of Staphylococcus aureus endocarditis, Severien Meyers, Leuven

Chairs: Alain Gadisseur and Kristel Vandenbosch
BSTH.3.3 – 11.45 – 12.00 Presentation by the winner CSL Behring encouragement award

12.00
12.40

Lunch

12.40
12.45

Opening

Frits Rosendaal, The Netherlands and Cécile Oury, Belgium

12.45
13.30

Keynote Lecture

Chairs: Cécile Oury, Belgium and Frits Rosendaal, The Netherlands
Inherited platelet disorders – Genomics, Kathleen Freson, Belgium

13.30
13.45

Short Break

13.45
14.45

Oral Communications

Chair: Tilman Hackeng, The Netherlands

OP 1.1 – 13.45 – 13.57: Selective serotonin reuptake inhibitor use is associated with major bleeding during treatment with vitamin K antagonists: results of a cohort study, Louise Burggraaf, The Netherlands

OP 1.2 – 13.57 – 14.09: Critical role of fibrin gamma-chain crosslinking by FXIIIa in preventing thrombus fragmentation and subsequent embolisation, Cédric Duval, United Kingdom

OP 1.3 – 14.09 – 14.21: Platelet-specific acetyl-CoA carboxylase 1 deletion decreases phospholipid content and impairs platelet functions, Marie Octave, Belgium

OP 1.4 – 14.21 – 14.33: TLR3 promotes venous thrombosis through endothelial cell activation, Maria Najem, France

OP 1.5 – 14.33 – 14.45: Exploring new candidate mechanisms behind antithrombin deficiency in cases with unknown molecular basis: mosaicism and intronic profiles, Pedro Garrido-Rodríguez, Spain

14.45
15.30

Keynote Lecture

Chair: Pierre Morange, France
How the exposome impacts the trajectory of age related health and disease, Paul Shiels, United Kingdom

15.30
16.00

Coffee Break and Poster Viewing

16.00
17.00

Oral Communications

Chairs: Johanna Gebhard, Austria and Pierre Morange, France

OP 2.1 – 16.00 – 16.12: A hemostatic chemical compound against bleedings induced by direct oral anticoagulants., Maximilien Desvages, France

OP 2.2 – 16.12 – 16.24: Presence and evolution of NET markers and DAMPS in critically ill COVID-19 patients, Joram Huckriede, The Netherlands

OP 2.3 – 16.24 – 16.36: Global seroprevalence of pre-existing immunity against AAV serotypes in people with hemophilia A, Brigitte Pan-Petesch, France

OP 2.4 – 16.36 – 16.48: Hypoxia augments proinflammatory activation of endothelial cells towards a prothrombotic phenotype, Casper Ullsten-Wahlund, Norway

OP 2.5 – 16.48 – 17.00: Derivation of a predictive score for venous thromboembolism in women using combined oral contraceptives, Pierre Suchon, France

17.00
18.00

Science, Fast and Furious

Chairs: Sara Arcudi, Italy and Tom van de Berg, The Netherlands

SFF1.1 – 17.00 – 17.15: Correlation of calibrated automated thrombogram parameters with clinical phenotype in a large cohort of patients with antithrombin deficiency carrying different SERPINC1 variants, Carlos Bravo-Perez, Spain

SFF1.2 – 17.15 – 17.30: Inhibition of ADAMTS13 Rescues Acquired von Willebrand Syndrome in a Preclinical Left Ventricular Assist Device Animal Model, Shannen J. Deconinck, Belgium

SFF1.3 – 17.30 – 17.45: S100A8/A9 levels are increased in COVID-19 patients and induce procoagulant platelets in a GPIbα-dependent manner, Martina Colicchia, United Kingdom

SFF1.4 17.45 – 18.00: Protease Nexin-1, a serpine participating in neutrophil recruitment through CD11a integrin regulation, Célina Madjene, France

18.00
20.00

Poster Awards and Welcome Reception

08.30
09.30

Oral Communications

Chairs: Sabine Eichinger, Austria and Zsuzsa Bagoly, Hungary

OP 3.1 – 08.30 – 08.42: Genetic and clinical determinants of the outcome of immune tolerance induction in severe hemophilia A – preliminary results, Ilja Oomen, The Netherlands

OP 3.2 – 08.42 – 08.54: The Extracellular Protease EpiP from S. aureus Triggers Blood Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1, Vincenzo De Filippis, Italy

OP 3.3 – 08.54 – 09.06: Activation mechanism dependent surface exposure of cellular FXIII on platelets and platelet microparticles: immunofluorescence and immune electron microscopic study, László Muszbek, Hungary

OP 3.4 – 09.06 – 09.18: Protein S Gla domain as theranostic for early vascular calcification, Anouk Gentier, Belgium

OP 3.5 – 09.18 – 09.30: Remote history of venous thrombosis and the risk of venous thrombosis beyond the age of 70 years, Huijie Wang, The Netherlands

09.30
10.15

Keynote Lecture

Chair: Karen Vanhoorelbeke, Belgium
Haemophilia and gene therapy, Cedric Hermans, Belgium

10.15
10.45

Coffee Break and Poster Viewing

10.45
11.45

Oral Communications

Chair: Anouk Gentier, The Netherlands

OP 4.1 – 10.45 – 10.57: COVID-19 associated coagulopathy in acute ischemic stroke patients treated with intravenous thrombolysis, Zsuzsa Bagoly, Hungary

OP 4.2 – 10.57 – 11.09: Joint effect of multiple prothrombotic genotypes and mean platelet volume on the risk of incident venous thromboembolism, Lisa Jakobsen, Norway

OP 4.3 – 11.09 – 11.21: Shear-induced platelet GPIbα shedding under extracorporeal membrane oxygenation promotes platelet clearance independently from von Willebrand factor-GPIbα interaction, Annabelle Dupont, France

OP 4.4 – 11.21 – 11.33: Effects of dietary palmitate on blood lipid profile and calcification of aorta and aortic valve, Nathalie Donis, Belgium

OP 4.5 – 11.33 – 11.45: Lower excess mortality in an anticoagulated population during the first wave of the COVID-19 pandemic in the Netherlands, Qingui Chen, The Netherlands

11.45
12.15

Meet the expert

Location: Minneplein

12.15
13.00

Lunch

13.00
14.00

Oral Communications

Chairs: John-Bjarne Hansen, Norway and Sofia Melo, Belgium

OP 5.1 – 13.00 – 13.12: A novel quali-quantitative defect of VWF, Tom van de Berg, The Netherlands

OP 5.2 – 13.12 – 13.24: Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura, Laure De Waele, Belgium

OP 5.3 – 13.24 – 13.36: GPVI is a binding partner for pro-coagulant factor VIII on platelets, Rohini Sekar, France

OP 5.4 – 13.36 – 13.48: Highly reactive juvenile platelets express higher levels of GPVI in a size-related manner, Alicia Veninga, The Netherlands

OP 5.5 – 13.48 – 14.00: SARS-CoV2 associated venous thromboembolism – a one-year follow-up, Alberto Maino, Italy

14.00
14.15

Short Break

14.15
15.15

Oral Communications

Chairs: Cédric Duval, United Kingdom and Thomas Vanassche, Belgium

OP 6.1 – 14.15 – 14.27: Prosthetic valve bioactive surface coating to reduce the prevalence of thrombosis, Cecile Oury, Belgium

OP 6.2 – 14.27 – 14.39: Venous Thromboembolism after Incident Colorectal Cancer in the Netherlands: Incidence, Predictors, and Prognosis, Rayna Anijs, The Netherlands

OP 6.3 – 14.39 – 14.51: Identification of two new ligands of the platelet CLEC-2 receptor, Luis A. Moran, United Kingdom

OP 6.4 – 14.51 – 15.03: Elevated plasma levels of the complement activating enzyme MASP-2 are associated with risk of future incident venous thromboembolism, Christabel Esi Damoah, Norway

OP 6.5 – 15.03 – 15.15: Role of Matrix Gla Protein in vascular calcification: hard chemistry for soft vessels, Stijn Agten, The Netherlands

15.15
15.45

Coffee Break and Poster Viewing

15.45
16.30

Keynote Lecture

Chair: Tilman Hackeng, The Netherlands
Venous thrombosis: From population studies to biological understanding, John-Bjarne Hansen, Norway

16.30
16.45

ECTH Closing

Register now for ECTH2021!